NVCR
NovoCure Ltd.
NASDAQ · Healthcare · Medical - Instruments & Supplies · JE
$14.59
+8.64%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 725.4M | 655.4M | 605.2M | 509.3M | 537.8M |
| Cost of Revenue | 166.7M | 166.9M | 137.2M | 128.3M | 114.9M |
| Gross Profit | 558.7M | 488.5M | 468.0M | 381.1M | 423.0M |
| Operating Expenses | |||||
| R&D Expense | 228.8M | 224.5M | 209.6M | 223.1M | 206.1M |
| SG&A Expense | 454.4M | 417.7M | 428.9M | 390.9M | 306.4M |
| General & Admin Expense | 212.4M | 177.7M | 189.8M | 164.1M | 132.8M |
| Selling & Marketing Expense | 242.0M | 240.1M | 239.1M | 226.8M | 173.7M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 683.2M | 642.3M | 638.5M | 614.7M | 512.5M |
| Cost and Expenses | 849.9M | 809.2M | 775.7M | 742.2M | 627.4M |
| Operating Income (EBIT) | (124.5M) | (153.8M) | (170.5M) | (232.9M) | (89.5M) |
| Non-Operating | |||||
| Interest Income | — | 18.1M | 51.0M | 46.0M | 15.8M |
| Interest Expense | 7.9M | — | 11.7M | 4.9M | 8.1M |
| Net Interest Income | (7.9M) | 18.1M | 39.3M | 41.1M | 7.7M |
| Other Non-Op Income/Expense | (6.0M) | 17.6M | 39.3M | 41.1M | 7.7M |
| Non-Operating Income (excl Interest) | (3.3M) | (17.6M) | (49.7M) | (44.4M) | (11.0M) |
| EBT (Pre-Tax Income) | (130.5M) | (136.3M) | (131.2M) | (191.7M) | (81.8M) |
| Income Tax Expense | (8.8M) | (23.0K) | 37.5M | 15.3M | 10.7M |
| Bottom Line | |||||
| Net Income | (121.7M) | (136.2M) | (168.6M) | (207.0M) | (92.5M) |
| Earnings from Cont. Ops | (121.7M) | (136.2M) | (168.6M) | (207.0M) | (92.5M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (121.7M) | (136.2M) | (168.6M) | (207.0M) | (92.5M) |
| Per Share | |||||
| Basic EPS | ($1.06) | ($1.22) | ($1.56) | ($1.95) | ($0.88) |
| Diluted EPS | ($1.06) | ($1.22) | ($1.56) | ($1.95) | ($0.88) |
| Revenue Per Share | $6.21 | $5.88 | $5.61 | $4.79 | $5.14 |
| Shares | |||||
| Basic Shares Outstanding | 116.8M | 111.5M | 107.8M | 106.4M | 104.7M |
| Diluted Shares Outstanding | 116.8M | 111.5M | 107.8M | 106.4M | 104.7M |
| Profitability Metrics | |||||
| EBITDA | (104.2M) | (121.6M) | (109.6M) | (177.5M) | (67.9M) |
| D&A | 17.1M | 14.7M | 11.2M | 11.0M | 10.6M |
| EBIT | (121.3M) | (136.3M) | (120.8M) | (188.4M) | (78.5M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026